LifeVantage Announces Expanded Human Clinical Study for MindBody GLP-1 System™; Findings Increase Average in Natural GLP-1 Production to Over 200%‡‡

SALT LAKE CITY, July 22, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced new results from its second human clinical study on the MindBody GLP-1 System™, revealing even more compelling outcomes across a broader participant base.

Read more at globenewswire.com